Last Updated: 08/06/2026

Poolbeg Pharma

London

Founded 2021

Clinical-stage biopharma targeting cancer immunotherapy and obesity

Poolbeg Pharma is a clinical-stage biopharmaceutical company developing small molecule therapies for high unmet medical needs.

Its lead programme, POLB 001, is a p38 MAP kinase inhibitor in clinical trials for prevention of cytokine release syndrome associated with CAR-T and bispecific antibody cancer immunotherapies.

A second programme is developing an oral encapsulated GLP-1 receptor agonist for obesity.

The company uses a capital-light, partnering-focused development model and holds AIM listing on the London Stock Exchange.

Biopharma Drug Discovery Oncology Infectious Disease

Small Molecule Drugs Metabolic Disease Rare Diseases

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of

BioIndustry Association

Similar Companies

Alchemab Therapeutics

London